HUMAN GENE THERAPY

Scope & Guideline

Fostering Collaboration in Gene Therapy Research

Introduction

Explore the comprehensive scope of HUMAN GENE THERAPY through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore HUMAN GENE THERAPY in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1043-0342
PublisherMARY ANN LIEBERT, INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1990 to 2024
AbbreviationHUM GENE THER / Hum. Gene Ther.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801

Aims and Scopes

The journal 'Human Gene Therapy' focuses on the latest advancements in gene therapy, emphasizing innovative approaches to treat genetic disorders and related diseases. Its scope encompasses a wide variety of topics, including gene editing technologies, vector development, and clinical applications of gene therapy.
  1. Gene Therapy Development and Application:
    The journal highlights research dedicated to developing new gene therapy techniques and their applications in clinical settings. This includes studies on various diseases, particularly genetic disorders.
  2. Gene Editing Technologies:
    There is a strong emphasis on novel gene editing technologies, including CRISPR/Cas9 and related systems, which are explored for their potential to correct genetic defects.
  3. Viral Vector Innovations:
    Research on viral vectors, especially adeno-associated viruses (AAV), plays a crucial role in the journal. Studies focus on enhancing vector efficiency, specificity, and safety for delivering therapeutic genes.
  4. Clinical Trials and Translational Research:
    The journal publishes findings from clinical trials, contributing to the understanding of gene therapy's efficacy and safety in human populations. This includes phase I/II studies and long-term follow-up assessments.
  5. Mechanisms of Gene Therapy:
    Investigations into the underlying mechanisms of gene therapy, including immune responses, vector biodistribution, and gene expression regulation, are central to the journal's contributions.
The landscape of gene therapy research is rapidly evolving, with several emerging themes gaining traction. These trends highlight the journal's adaptability and responsiveness to the latest scientific advancements and societal needs.
  1. Advancements in CRISPR Technology:
    Recent publications show a significant increase in research related to CRISPR technology, including novel applications, improved precision, and safety measures in gene editing.
  2. Combination Therapies:
    There is a growing trend towards exploring combination therapies that integrate gene therapy with other treatment modalities, such as immunotherapy, to enhance efficacy against complex diseases.
  3. Personalized Gene Therapies:
    Research focusing on personalized medicine approaches, where therapies are tailored to individual genetic profiles, is on the rise, reflecting a broader trend in precision medicine.
  4. Gene Therapy for Rare Diseases:
    An increasing number of studies are dedicated to developing gene therapies for rare diseases, driven by the need for effective treatments for conditions that have limited options.
  5. Regulatory and Ethical Considerations:
    Emerging discussions around the regulatory landscape, ethical considerations, and the societal implications of gene therapy are becoming more prevalent in the journal, indicating a maturation of the field.

Declining or Waning

While 'Human Gene Therapy' continues to thrive in many areas, certain themes appear to be declining in prominence over recent years. These waning scopes reflect shifts in research focus or advancements in technology that have rendered previous topics less critical.
  1. Traditional Gene Therapy Approaches:
    There has been a noticeable decline in studies focused solely on traditional gene therapy methods, as more advanced techniques like CRISPR and other gene editing technologies gain traction.
  2. Basic Research on Gene Delivery Mechanisms:
    Basic studies exploring the mechanisms of gene delivery have decreased, likely due to the shift towards more applied research that directly informs clinical practices and safety assessments.
  3. Single-Gene Disorders Focus:
    Research specifically targeting single-gene disorders may be waning as the field broadens to encompass more complex genetic conditions and polygenic disorders, which require multifaceted therapeutic approaches.

Similar Journals

TRENDS IN MOLECULAR MEDICINE

Pioneering Discoveries for Tomorrow's Health
Publisher: CELL PRESSISSN: 1471-4914Frequency: 12 issues/year

TRENDS IN MOLECULAR MEDICINE, published by CELL PRESS, is a premier journal that stands at the forefront of the rapidly evolving fields of molecular biology and molecular medicine. With a distinguished Q1 ranking in both categories and an impressive Scopus standing—ranked #12 out of 410 in Molecular Biology and #6 out of 178 in Molecular Medicine—this journal is a vital source of high-impact research and insights for researchers, professionals, and students alike. The journal, which has been published consistently since 2000, promotes the dissemination of groundbreaking discoveries that bridge the gap between molecular biology and therapeutic applications. Furthermore, TRENDS IN MOLECULAR MEDICINE embraces modern accessibility options, engaging a global audience eager to explore pioneering advancements in human health. Set against the backdrop of the United Kingdom, this esteemed publication not only informs but also inspires ongoing research and innovation in molecular sciences, making it an essential resource for those shaping the future of medicine.

Lancet Haematology

Connecting researchers and clinicians for better patient outcomes.
Publisher: ELSEVIER SCI LTDISSN: 2352-3026Frequency: 12 issues/year

Lancet Haematology, published by Elsevier Science Ltd in the United Kingdom, is a premier peer-reviewed journal dedicated to advancing the field of hematology. With an impressive impact factor and listed in the Q1 category in hematology for 2023, this journal ranks #4 out of 137 in the Scopus database, boasting a 97th percentile indicating its influential role in disseminating high-quality research. Since its establishment in 2014, Lancet Haematology has provided a vital platform for researchers and clinicians to share groundbreaking studies, innovative treatment approaches, and novel therapeutic discoveries relevant to various hematological disorders. The journal does not operate under an open access model, but it offers multiple access options to facilitate engagement with its content. By bridging clinical practice and cutting-edge research, Lancet Haematology aims to foster the advancement of knowledge and improve patient outcomes in hematology, making it an essential read for professionals, researchers, and students alike.

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Unveiling the complexities of genetics and clinical applications.
Publisher: SPANDIDOS PUBL LTDISSN: 1107-3756Frequency: 12 issues/year

International Journal of Molecular Medicine is a prestigious publication dedicated to advancing the field of molecular medicine through innovative research and scholarly dialogue. Published by Spandidos Publications Ltd in Greece, this journal has successfully provided a platform for academics and professionals alike since its inception in 1998. With an impressive 2023 Q1 ranking in Medicine (Miscellaneous) and a Q2 ranking in Genetics, the journal maintains a vital role in disseminating high-quality research, underscored by its strong performance in the Scopus rankings, particularly in the realm of genetics where it ranks 28 out of 347. Researchers will benefit from its comprehensive scope, which encompasses a wide range of topics within molecular biology, genetics, and their clinical applications. Although the journal does not operate under an open access model, it remains influential, providing critical insights that contribute significantly to the understanding and development of molecular therapeutic strategies and innovations.

CURRENT OPINION IN GENETICS & DEVELOPMENT

Pioneering advancements in developmental processes.
Publisher: CURRENT BIOLOGY LTDISSN: 0959-437XFrequency: 6 issues/year

CURRENT OPINION IN GENETICS & DEVELOPMENT is a prestigious journal published by CURRENT BIOLOGY LTD that offers an insightful platform for the latest developments and emerging trends in the fields of genetics and developmental biology. Established in 1991 and set to continue until at least 2024, this journal achieves notable recognition in the academic community with a Q1 classification in both its major categories as of 2023. With a Scopus rank placing it within the top quartile for both genetics and developmental biology, it serves as an essential resource for researchers, professionals, and students seeking to enhance their understanding of genetic mechanisms and developmental processes. While currently not an open-access journal, readers can explore the collection of high-quality articles that contribute to shaping contemporary scientific discourse and fostering innovation within these dynamic fields. For those dedicated to advancing their research and knowledge, CURRENT OPINION IN GENETICS & DEVELOPMENT stands as a vital and influential academic publication.

FUNCTIONAL & INTEGRATIVE GENOMICS

Connecting Genomic Research with Real-World Applications
Publisher: SPRINGER HEIDELBERGISSN: 1438-793XFrequency: 4 issues/year

FUNCTIONAL & INTEGRATIVE GENOMICS, published by Springer Heidelberg, is a leading journal in the fields of genetics and molecular biology. Established in 2000, it serves as a pivotal platform for advancing our understanding of genomic functionality and integration, making significant contributions to both basic and applied research in genetics. With a robust impact factor and a ranking in the Q3 quartile for Genetics and Q2 for Medicine (Miscellaneous), the journal aims to publish innovative research that explores the relationships between genomic data and biological functions, appealing to a diverse audience of researchers and professionals. Although it operates under a subscription model, the journal's extensive archives remain a valuable resource for academics seeking to stay abreast of the latest findings and methodologies in genomics. As the field evolves, FUNCTIONAL & INTEGRATIVE GENOMICS remains committed to fostering scholarly dialogue and the dissemination of groundbreaking studies that influence future research trajectories.

JOURNAL OF GENE MEDICINE

Innovating Molecular Medicine for Tomorrow
Publisher: WILEYISSN: 1099-498XFrequency: 12 issues/year

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

RUSSIAN JOURNAL OF GENETICS

Uncovering the Mysteries of Heredity and Variation
Publisher: PLEIADES PUBLISHING INCISSN: 1022-7954Frequency: 12 issues/year

RUSSIAN JOURNAL OF GENETICS is a significant platform in the field of genetics, published by PLEIADES PUBLISHING INC since its inception in 1996. With an ISSN of 1022-7954 and an E-ISSN of 1608-3369, the journal focuses on a wide array of topics within genetics, providing researchers, professionals, and students with insights into advancements and discoveries in this ever-evolving discipline. While it currently holds a Q4 ranking in the 2023 Genetics category according to Scopus, representing invaluable opportunities for knowledge dissemination, the journal is actively working to enhance its impact in future rankings. Readers will find the journal a repository of diverse genetic research findings, methodologies, and theoretical advancements. Although it is not an open-access journal, it is committed to serving the academic community through rigorous peer-reviewed articles. With a consistent publication trajectory spanning to 2024, the RUSSIAN JOURNAL OF GENETICS remains a crucial resource for those aspiring to stay at the forefront of genetic research and applications.

Blood Advances

Empowering Researchers in Blood Advances
Publisher: ELSEVIERISSN: 2473-9529Frequency: 24 issues/year

Blood Advances is a premier, peer-reviewed journal published by Elsevier, dedicated to the field of hematology. With an impressive impact factor and classified within the Q1 category of hematology for 2023, it ranks as the 16th out of 137 journals in the Scopus Medicine Hematology category, placing it in the top 88th percentile globally. This influential journal, which has been disseminating invaluable research since its inception in 2017, focuses on advancing knowledge and innovation in blood science, including clinical and laboratory aspects of hematology. Although it offers limited open access features, its comprehensive scope encompasses various topics relevant to both researchers and practitioners. Located in the United States and managed from Amsterdam, Blood Advances provides a vital platform for the dissemination of groundbreaking research, making significant contributions to the understanding and treatment of blood disorders. Researchers, professionals, and students alike will find this journal an essential resource for keeping abreast of the latest developments and advancements in hematology.

CYTOTHERAPY

Leading the Charge in Cell Biology and Immunology.
Publisher: ELSEVIER SCI LTDISSN: 1465-3249Frequency: 12 issues/year

CYTOTHERAPY is a distinguished journal published by Elsevier Science Ltd, focusing on the critical fields of cell therapy, transplantation, and regenerative medicine. Since its inception in 1999, the journal has established itself as a vital resource for researchers and practitioners, contributing significantly to advancements in Cancer Research, Cell Biology, Genetics, Immunology, and Oncology. With an impressive range of Q2 rankings across multiple categories and a remarkable Q1 standing in Transplantation for 2023, CYTOTHERAPY delivers high-impact research that addresses the evolving challenges in these fields. While the journal does not offer open access, it remains a reputable avenue for disseminating pivotal studies and reviews that push the boundaries of cell-based therapies. Researchers, clinicians, and students alike will find CYTOTHERAPY an indispensable platform to stay abreast of the latest discoveries and innovations that are shaping the future of medical science.

HEMOGLOBIN

Decoding the mysteries of blood disorders.
Publisher: TAYLOR & FRANCIS LTDISSN: 0363-0269Frequency: 6 issues/year

HEMOGLOBIN, a prominent journal published by Taylor & Francis Ltd, serves as a vital resource in the fields of Biochemistry, Clinical Biochemistry, Genetics, and Hematology. Established in 1976, the journal provides a platform for innovative research and review articles that explore the complexities of hemoglobin pathology and related disorders, making significant contributions to our understanding of hematological diseases. With an ISSN of 0363-0269 and an E-ISSN of 1532-432X, HEMOGLOBIN has garnered attention within the academic community, reflected in its category quartiles for 2023, which rank it in the Q3 and Q4 levels across relevant medical and biochemistry categories. Although it operates on a subscription basis rather than as an open-access journal, it remains influential, providing critical insights to researchers, professionals, and students aiming to address the current challenges in blood research and related fields. The journal not only emphasizes high-quality scientific analyses but also seeks to foster collaboration and dialogue among academia and clinical practitioners, ultimately advancing the frontier of knowledge in hemoglobin and hematological research.